The spatial distribution of four neurochemicals (GAP-43, SYN, GABAa receptor, and CAMKIIα) in relation to normal and glaucomatous eye bands was studied. Sections from the left hemisphere were reacted histochemically for CO and immunohistochemically for GAP-43 and the GABAa receptor (β chain). Sections from the right hemisphere were reacted histochemically for CO and immunohistochemically for SYN and CAMKIIα. All immunohistochemistry was performed by reacting pairs of sections from visual and frontal cortex simultaneously.
Monoclonal antibody against GAP-43 was obtained from the GAP-7B10 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with HPLC-purified GAP-43 from neonatal rat forebrain membranes (Sigma-Aldrich Co.). It exhibits a wide interspecies cross-reactivity and was used to localize both phosphorylated and nonphosphorylated forms of GAP-43 in the primate visual cortex.
Monoclonal anti-SYN (Sigma-Aldrich Co.) was obtained from a hybridoma produced by mouse myeloma cells and splenocytes from an immunized mouse. A synaptosome preparation from rat retina was used as the immunogen.
A monoclonal antibody against γ-aminobutyric acid/benzodiazepine (GABAa) receptors (β-chain, clone bd 17) from mouse-mouse hybrid cells (Roche Molecular Biochemicals, Indianapolis, IN) was used to react with the β-chain of the GABAa receptor in the primate brain. This antibody was obtained by immunizing BALB/c mice with a highly purified GABA-benzodiazepine receptor preparation from bovine cortex.
29 It can cross-react with human GABAa with the same subunit specificity as in bovine brain. The β-subunit is present in all brain areas of human cerebral cortex.
30
A monoclonal antibody to the α subunit of Ca2+/calmodulin-dependent protein kinase type II (CAMKIIα) derived from mouse-mouse hybrid cells (clone 6G9) was used (Roche Molecular Biochemicals, Indianapolis, IN). The antibody was obtained by immunizing BALB/c mice with purified type II CAM protein kinase from the synaptic vesicles isolated from rat brain. Lymphocytes from the immunized mouse spleens were fused with mouse myeloma cells of the cell line NS1/SP2. Anti-CAMKIIα detects a 50-kDa protein and reacts specifically with the α-subunit in all mammalian cells.
For GAP-43, SYN, and the GABAa receptor, sections of primary visual cortex were incubated in 5% to 10% normal horse serum (NHS) for 1 hour to block nonspecific binding. Sections were then washed three times for 5 minutes each in PB. GAP-43 and SYN antibodies were used at a 1:2000 dilution in 3% NHS in 0.1% Triton X-100 (TX100) made in PB. Antibody against GABAa receptor was used at a 1:200 dilution in 3% NHS in 0.1% TX100. For CAMKIIα immunoreactivity, sections were preincubated in 0.2% TX100 for 15 minutes, according to the manufacturer’s protocol, before incubation in a 1:1000 dilution in 3% NHS in 0.1% TX100. All immunostained sections were agitated and incubated at 4°C in primary antibody for 36 to 48 hours. Sections were washed three times for 5 minutes each in 0.1% TX100 before being incubated for 2 hours at room temperature in 0.1% secondary antibody (biotinylated anti-mouse made in horse) in 3% NHS in 0.3% TX100 made in PB. Before incubation with the avidin biotin complex for 1 hour, sections were washed three times for 5 minutes each in PB. Antibodies were visualized by using the glucose oxidase-DAB reaction in which 10 mg of DAB, 40 mg dextrose, and 8 mg ammonium chloride are dissolved in 20 mL of PB. Sections were preincubated in the DAB solution for 10 minutes. Next, glucose oxidase (6 mg glucose oxidase in 50 mL distilled water) was added to the DAB solution at a 1:10 ratio, and the reaction proceeded in the dark for 45 minutes. Sections were then rinsed three times in PB for 5 minutes, mounted onto gelatin-coated slides, air dried, dehydrated through an ascending concentration of alcohols, cleared in xylene, and coverslipped in mounting medium (Permount; Fisher Scientific, Fair Lawn, NJ). Control sections for each marker used the same protocol, except that the primary antibody was omitted.